The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.
More Latest News
November 15, 2023
MQA is planning to revamp the board websites. Please take the survey to give us your recommendations by clicking the survey icon below. Continue reading
November 1, 2023
An annual publication showcasing trends and information about Florida’s health care regulatory landscape. Continue reading